Biovica share price explodes upon news and successfull offeringAdded this very promising swedish company to my watch list. Bit late to this party, but looking to buy if the usual sell the news shenanigans occur.
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments.
Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials.
The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer.
Biovica collaborates with world-leading cancer institutes and pharmaceutical companies.
DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth
